Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (51-60 of 222) with videos related to

Pageof 23
Sort By:
The Journal of Biological Chemistry|February 11, 2009
Calcineurin activates cytoglobin transcription in hypoxic myocytesSarvjeet Singh, Shilpa M Manda, Devanjan Sikder, et al.
Gynecologic Oncology|July 13, 2010
Up-regulation of stromal versican expression in advanced stage serous ovarian cancerSue Ghosh, Lina Albitar, Richard LeBaron, et al.
Gynecologic Oncology|October 8, 2003
Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpusWilliam E Winter, Jeffrey D Seidman, Thomas C Krivak, et al.
Breast Cancer Research and Treatment|December 5, 2002
Age-dependent changes in breast cancer hormone receptors and oxidant stress markersJudy Quong, Serenella Eppenberger-Castori, Dan Moore, et al.
Gynecologic Oncology|December 25, 2019
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancerRebecca C Arend, Allison M Davis, Przemyslaw Chimiczewski, et al.
Future Oncology (London, England)|February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancerKathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
Gynecologic Oncology|June 16, 2009
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group studyKathleen M Darcy, William E Brady, Jan K Blancato, et al.
Gynecologic Oncology|January 29, 2010
FGFR2 mutations are rare across histologic subtypes of ovarian cancerSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Oncogene|September 14, 2004
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathwaysHoward Donninger, Tomas Bonome, Mike Radonovich, et al.
The Journal of Biological Chemistry|December 7, 2007
Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activityCarlos E Irarrazabal, Chester K Williams, Megan A Ely, et al.
Pageof 23

Showing results (51-60 of 222) with videos related to

Sort By:
Pageof 23
The Journal of Biological Chemistry|February 11, 2009
Calcineurin activates cytoglobin transcription in hypoxic myocytesSarvjeet Singh, Shilpa M Manda, Devanjan Sikder, et al.
Gynecologic Oncology|July 13, 2010
Up-regulation of stromal versican expression in advanced stage serous ovarian cancerSue Ghosh, Lina Albitar, Richard LeBaron, et al.
Gynecologic Oncology|October 8, 2003
Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpusWilliam E Winter, Jeffrey D Seidman, Thomas C Krivak, et al.
Breast Cancer Research and Treatment|December 5, 2002
Age-dependent changes in breast cancer hormone receptors and oxidant stress markersJudy Quong, Serenella Eppenberger-Castori, Dan Moore, et al.
Gynecologic Oncology|December 25, 2019
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancerRebecca C Arend, Allison M Davis, Przemyslaw Chimiczewski, et al.
Future Oncology (London, England)|February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancerKathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
Gynecologic Oncology|June 16, 2009
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group studyKathleen M Darcy, William E Brady, Jan K Blancato, et al.
Gynecologic Oncology|January 29, 2010
FGFR2 mutations are rare across histologic subtypes of ovarian cancerSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Oncogene|September 14, 2004
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathwaysHoward Donninger, Tomas Bonome, Mike Radonovich, et al.
The Journal of Biological Chemistry|December 7, 2007
Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activityCarlos E Irarrazabal, Chester K Williams, Megan A Ely, et al.
Pageof 23